Menu Search
Equities

Sinphar Pharmaceutical Co Ltd

1734:TAI

Sinphar Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)31.15
  • Today's Change0.05 / 0.16%
  • Shares traded100.28k
  • 1 Year change+0.72%
  • Beta--
Data delayed at least 20 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in TWDIncome statement in TWDView more

Year on year Sinphar Pharmaceutical Co Ltd grew revenues 3.72% from 2.86bn to 2.96bn while net income improved 67.01% from 224.64m to 375.17m.
Gross margin38.51%
Net profit margin10.80%
Operating margin10.47%
Return on assets5.29%
Return on equity10.72%
Return on investment6.91%
More ▼

Cash flow in TWDView more

In 2023, cash reserves at Sinphar Pharmaceutical Co Ltd fell by 163.07m. However, the company earned 296.37m from its operations for a Cash Flow Margin of 10.00%. In addition the company used 334.56m on investing activities and also paid 120.67m in financing cash flows.
Cash flow per share3.16
Price/Cash flow per share9.84
Book value per share17.56
Tangible book value per share17.15
More ▼

Balance sheet in TWDView more

Sinphar Pharmaceutical Co Ltd has a Debt to Total Capital ratio of 34.35%, a lower figure than the previous year's 49.51%.
Current ratio2.27
Quick ratio1.58
Total debt/total equity0.5708
Total debt/total capital0.3435
More ▼

Growth rates in TWD

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 8.00% and 66.99%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is the highest in its industry.
Div yield(5 year avg)1.83%
Div growth rate (5 year)60.95%
Payout ratio (TTM)50.40%
EPS growth(5 years)111.82
EPS (TTM) vs
TTM 1 year ago		20.24
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.